SAMPLE. Dyslexia Global Clinical Trials Review, H1, Reference Code: GDHC2573CTIDB. Publication Date: FEB 2015

Transcription

1 Dyslexia Global Clinical Trials Review, H1, 2015 Reference Code: GDHC2573CTIDB Publication Date: FEB 2015 Page 1

2 Table of Contents Table of Contents... 2 List of Tables... 3 List of Figures... 4 Introduction... 5 Dyslexia... 5 Symptoms of dyslexia are:... 5 Report Guidance... 5 Clinical Trials by Region... 6 Clinical Trials and Average Enrollment by Country... 7 Top Countries Contributing to Clinical Trials in Asia-Pacific... 9 Top Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Countries Contributing to Clinical Trials in Middle East and Africa Clinical Trials by G7 Countries: Proportion of Dyslexia to Central Nervous System Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Prominent Drugs Clinical Trial Profiles Clinical Trial Overview of Top Companies Eli Lilly and Company Clinical Trial Overview of Eli Lilly and Company Clinical Trial Overview of Top Institutes / Government Eunice Kennedy Shriver National Institute of Child Health and Human Development Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development National Stroke Foundation Clinical Trial Overview of National Stroke Foundation University of Tasmania Clinical Trial Overview of University of Tasmania University of Munster Clinical Trial Overview of University of Munster Rehabilitation Hospital of The Pacific Clinical Trial Overview of Rehabilitation Hospital of The Pacific University of Oxford Clinical Trial Overview of University of Oxford Vanderbilt University Clinical Trial Overview of Vanderbilt University U.S. Department of Veterans Affairs Clinical Trial Overview of U.S. Department of Veterans Affairs Page 2

3 Rabin Medical Center Clinical Trial Overview of Rabin Medical Center Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About GlobalData Disclaimer Source List of Tables Dyslexia Therapeutics, Global, Clinical Trials by Region, 2015*... 6 Dyslexia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*... 7 Dyslexia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*... 8 Dyslexia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015*... 9 Dyslexia Therapeutics Clinical Trials, Europe, Top Countries, 2015* Dyslexia Therapeutics Clinical Trials, North America, Top Countries, 2015* Dyslexia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* Proportion of Dyslexia to Central Nervous System Clinical Trials, G7 Countries (%), 2015* Dyslexia Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* Dyslexia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* Dyslexia Therapeutics, Global, Clinical Trials by Phase, 2015* Dyslexia Therapeutics, Global, Clinical Trials In Progress by Phase 2015* Dyslexia Therapeutics, Global, Clinical Trials by Trial Status, 2015* Dyslexia Therapeutics Clinical Trials, Global, by End Point Status, 2015* Dyslexia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, Dyslexia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* Dyslexia Therapeutics Clinical Trials, Global, Key Sponsors, 2015* Dyslexia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Stroke Foundation, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Tasmania, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Munster, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Rehabilitation Hospital of The Pacific, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2015* Dyslexia Therapeutics Clinical Trials Market, Global, Clinical Trials by Rabin Medical Center, 2015* Page 3

4 List of Figures Dyslexia Therapeutics, Global, Clinical Trials by Region (%), 2015*... 6 Dyslexia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*... 7 Dyslexia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*... 8 Dyslexia Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* Proportion of Dyslexia to Central Nervous System Clinical Trials, G7 Countries (%), 2015* Dyslexia Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* Dyslexia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* Dyslexia Therapeutics, Global, Clinical Trials by Phase (%), 2015* Dyslexia Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* Dyslexia Therapeutics, Global, Clinical Trials by Trial Status, 2015* Dyslexia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, Dyslexia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* Dyslexia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* GlobalData Methodology Page 4

5 Introduction Dyslexia Dyslexia (also known as developmental reading disorder) is a reading disability resulting from the inability to process graphic symbols. Developmental reading disorder (DRD) is not caused by vision problems, but rather by problems with the brain's ability to recognize and process symbols. Children with DRD may have trouble in rhyming and separating the sounds in spoken words. These abilities appear to be critical in the process of learning to read. Symptoms of dyslexia are: Difficulty in determining the meaning (idea content) of a simple sentence Difficulty in learning to recognize written words Difficulty in rhyming May occur in combination with writing or arithmetic learning problems Report Guidance Dyslexia Global Clinical Trials Review, H1, 2015 outlines clinical trials in Dyslexia. The prominent features of this report are - 1. Comprehensive data related to Dyslexia clinical trials by region, country, phase, and recruitment status 2. Clinical trials conducted by key Companies and Institutes. The selection of the sponsors is based on the total number of Dyslexia clinical trials conducted 3. Prominent drugs are provided based on number of ongoing clinical trials 4. The trials compiled in this report are from clinical trial registries, conferences, journals etc Page 5

6 Clinical Trials by Region Dyslexia Therapeutics, Global, Clinical Trials by Region (%), 2015* Dyslexia Therapeutics, Global, Clinical Trials by Region, 2015* North America Europe Asia-Pacific Middle East and Africa Locations Not Specified Total World Zones Number of Clinical Trials Page 6

7 Dyslexia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* Dyslexia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* United States United Kingdom Israel Germany Finland Australia Total Country Name Number of Clinical Trials (In Progress) Page 8

8 Top Countries Contributing to Clinical Trials in Asia-Pacific Dyslexia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* Australia Total Country Name Number of Clinical Trials Page 9

9 Top Countries Contributing to Clinical Trials in Europe Dyslexia Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* Dyslexia Therapeutics Clinical Trials, Europe, Top Countries, 2015* United Kingdom Germany Finland Total Country Name Number of Clinical Trials Page 10

10 Appendix Abbreviations BRIC: Brazil, Russia, India and China Definitions PHASE I TRIALS: Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and were intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide an adequate basis for physician labeling. PHASE IV TRIALS: Post-marketing studies to delineate additional information including the drug's risks, benefits, and optimal use. TRIAL STATUS: Indicates the current stage of a trial, whether it is planned, ongoing, or completed. Possible values include: Trial in Progress: This is inclusive of; Planned: participants were not yet being recruited or enrolled Recruiting: participants were currently being recruited and enrolled Enrolling by invitation: participants were being (or will be) selected from a predetermined population Active, not recruiting: study is ongoing (i.e., patients were being treated or examined), but enrollment has completed Completed: the study has concluded normally; participants were no longer being examined or treated (i.e., last patient's last visit has occurred) Suspended: recruiting or enrolling participants has halted prematurely but potentially will resume Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants were no longer being examined or treated Withdrawn: study halted prematurely, prior to enrollment of first participant SUBJECTS RECRUITED: The number of patients so enrolled for the trial in concern, to be analyzed. UNACCOMPLISHED TRIALS: The category comprising of the terminated, withdrawn and suspended trials. Page 59

11 Research Methodology GlobalData dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in marketing, market research and consulting in the pharmaceutical industry with advanced statistical expertise. GlobalData adheres to the Codes of Practice of the Market Research Society ( and the Society of Competitive Intelligence Professionals ( All GlobalData databases were continuously updated and revised. The following research methodology is followed for all databases and reports. GlobalData Methodology Source: GlobalData Secondary Research Data extraction from Pharma etrack Data Validation Data Analysis Self QC Quality check by QC Lead Submission of the Report The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market. The secondary research sources that were typically referred to include, but were not limited to: Company websites, annual reports, financial reports, broker reports, investor presentations and SEC Filings; Industry trade journals, scientific journals and other technical literature; Internal and external proprietary databases; Relevant patent and regulatory databases; National government documents, statistical databases and market reports; Procedure registries; and Page 60

12 News articles, press releases and web-casts specific to the companies operating in the market. About GlobalData We hope that the data and analysis in this brief will help you make informed and imaginative business decisions. If you have further requirements, GlobalData consulting team may be able to help you. GlobalData offers Tailor made analytical and advisory services to drive your key strategic decisions. Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData. Source Page 61